Bruker Daltonics Releases Novel MALDI BioTyper System for Protein Profiling of Microorganisms by MALDI-TOF Mass SpectrometryBru
13 March 2006 - 11:00PM
Business Wire
At Pittcon 2006, Bruker Daltonics today announces the release of
its novel MALDI BioTyper(TM) system for the identification and
classification of microorganisms using protein 'fingerprints'
measured by MALDI-TOF mass spectrometry. The characteristic protein
expression patterns of microorganisms, such as bacteria, yeasts and
fungi, can be analyzed with the new MALDI BioTyper system. The
remarkable reproducibility of the MALDI BioTyper is based on the
measurement of high-abundance proteins, including many ribosomal
proteins. As ribosomal proteins are part of the cellular
translational machinery, they are present in all living cells. As a
result, the MALDI BioTyper protein fingerprints are not
significantly influenced by variability in environmental or growth
conditions. This is a crucial advantage of this new microbiology
method, as it allows the generation of robust MALDI BioTyper
libraries of microorganisms. A more detailed application note is
available at www.bdal.de/biotyper The MALDI BioTyper represents an
excellent complement to classical microbiological identification
and classification techniques, and to modern PCR-based techniques.
In contrast to other approaches, the MALDI BioTyper does not
require any initial assessment like gram staining, oxidase test of
unknown samples, choice of PCR primers or usage of selective growth
media. Applications of the MALDI BioTyper include taxonomical
research on microorganisms, infectious disease research, as well as
microorganism detection and identification in environmental
analysis, food safety and water quality. Using standardized MALDI
BioTyper methods, after an overnight culture growth, cell material
can either be directly transferred onto a MALDI-TOF target plate,
or it can be analyzed after a rapid organic extraction procedure.
Excellent reproducibility can be achieved routinely even by
inexperienced users. Easy and cost-effective sample preparation
combined with rapid TOF data acquisition in seconds allows the
analysis of hundreds of samples within a day. Redundant
measurements are possible to further increase the level of
confidence. The MALDI BioTyper bioinformatics package performs the
microorganism identification and classification based on MALDI-TOF
proteomic signatures. The MALDI BioTyper software carries out all
necessary data processing steps leading from raw spectra to peak
lists. The generation of reference spectra for individual strains
is automated, but the software also allows for expert interaction.
Microorganism identification is performed by pattern matching
between reference spectra and MALDI-TOF profiles of unknown
strains. The analysis results are visualized in an intuitive
graphical user interface. In addition to enabling the
identification of known microorganisms, the MALDI BioTyper software
offers a variety of advanced algorithms for the characterization of
unknown microorganisms, including clustering and phylogenetic
dendrogram construction. This unique feature allows the protein
signature classification of unknown species and strains, and
uniquely complements taxonomical and phylogenetic approaches, such
as ribosomal DNA sequencing. The MALDI BioTyper typically achieves
identification at the genus or species level. In many cases even
different microbial strains can be distinguished. Dr. Thomas Maier,
the Bruker Daltonics MALDI BioTyper Project Manager, said: "The
idea of the MALDI BioTyper is to combine easy sample preparation,
state-of-the-art instrumentation and robust data analysis tools
into a next-generation technique for the fast, convenient and
cost-effective identification of microbial strains. Our customers
are very impressed by the facile and cost-effective sample
preparation used in our unique protein signature approach for
unequivocal microbial identification." Dr. Markus Kostrzewa,
Director of Clinical Proteomics R&D at Bruker Daltonics,
explained further: "An attractive aspect of the MALDI BioTyper is
that it fits seamlessly with our other MALDI-TOF based CLINPROT(TM)
clinical proteomics applications, such body-fluid profiling,
protein biomarker identification and validation, as well as MALDI
molecular imaging. The MALDI BioTyper is a further step in bringing
our mass spectrometry-based solutions into biology laboratories
where the same instrument can be used for multiple workflows in
life science and clinical research applications." Pittcon 2006, the
57th Pittsburgh Conference and Exposition on Analytical Chemistry
and Applied Spectroscopy, is being held from March 13-16 in
Orlando, Florida in the Orange County Convention Center. Bruker
Daltonics will exhibit at booth #3155. ABOUT BRUKER BIOSCIENCES
(NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in
Billerica, Massachusetts, is the publicly traded parent company of
Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading
developer and provider of life science, materials research, and
industrial X-ray analysis tools. Bruker Daltonics is a leading
developer and provider of innovative life science tools based on
mass spectrometry. Bruker Daltonics also offers a broad line of
nuclear, biological and chemical (NBC) detection products for
defense and homeland security. For more information, please visit
www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K for the year ended December 31, 2004, our most recent
quarterly reports on Form 10-Q, and our current reports on Form
8-K. We disclaim any intent or obligation to update these
forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024